H3B 6527

Drug Profile

H3B 6527

Alternative Names: H3B-6527

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Liver cancer

Most Recent Events

  • 08 Jan 2018 H3 Biomedicine plans a phase Ib trial for Cancer (Combination therapy) in 2018
  • 27 Dec 2017 Eisai in collaboration with H3 Biomedicine completes a phase I trial in Healthy volunteers in USA (NCT03424577)
  • 10 Oct 2017 H3B 6527 receives Orphan Drug status for liver cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top